Abstract：Objective: To investigate the clinical efficacy and safety of smegliptide in overweight or obese (T2DM) patients with type 2 diabetes mellitus. Methods: Eighty overweight or obese patients with T2DM admitted in Hanzhong Central Hospital, Shaanxi Province from January 2022 to June 2022 were enrolled for the study and divided into observation group (n = 40) and control group (n = 40) through simple random grouping method. On the basis of diet control and aerobic exercise, patients in the control group and observation group were metformin, metformin + smeglutide respectively. The blood glucose, body weight, blood lipid, blood pressure and adverse reactions were compared between the two groups before intervention and 12 weeks after intervention. Results: Compared with the level before the intervention within group, the fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (2hPPG), glycosylated hemoglobin (HbAlc), homeostasis model assessment of insulin resistance index (HOMA-IR), body mass index (BMI), total triglyceride (TG), total cholesterol (TC), systolic blood pressure (SBP) and diastolic blood pressure (DBP) in the two groups significantly decreased after the intervention, and the homeostasis model assessment of islet β cell function index (HOMA-β) significantly increased (P<0.05). Compared with the control group, the difference of FPG, 2hPPG, HbAlc, HOMA-IR, HOMA-β, BMI, SBP, DBP, TG, TC before and after intervention in observation group significantly increased (P<0.05). There were no significant differences in the incidences of adverse reactions between two groups (P>0.05). Conclusion: Smegliptide could not only significantly reduce the blood glucose level of T2DM patients with overweight or obese, but also strengthen the control of body weight, blood lipid and blood pressure, improve insulin resistance. It is safe, reliable and worthy of clinical application.
李燕妮, 刘红丽, 王叶菊, 王伊萌, 魏志, 苗群英, 郭秋野. 司美格鲁肽对超重及肥胖2型糖尿病患者的临床疗效及安全性分析[J]. 河北医学, 2023, 29(4): 582-587.
LI Yanni, LIU Hongli, WANG Yeju, et al. Clinical Efficacy and Safety Analysis of Emaglutide in Overweight and Obese Patients with Type 2 Diabetes Mellitus. HeBei Med, 2023, 29(4): 582-587.
2023, Vol. 29 
冀公网安备13080202000677号